ArticleBMJ public health2026
Assessing mpox knowledge, attitude and willingness to accept the mpox vaccine among people living with HIV and men who have sex with men in selected health facilities in Rivers State, Nigeria: a cross-sectional study.
Article in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Mpox vaccine acceptance and uptake in Africa: a systematic review and meta-analysis.BMC global and public health · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Limited data exist on the knowledge of and attitudes towards mpox and willingness to accept the repurposed mpox vaccine among vulnerable populations, such as people living with HIV (PLHIV) and men who have sex with men (MSM), in countries with overlapping HIV and mpox epidemics, like Nigeria. Methods: A cross-sectional study was conducted from 26 August 2024 to September 2024, involving 290 PLHIV and 14 MSM at two selected health facilities in Rivers State, Nigeria, using systematic and snowball sampling techniques, respectively. A self-administered web-based Google form was used to collect sociodemographic data, mpox knowledge, attitudes towards the disease and willingness to receive the mpox vaccine. The χ Results: Although most participants (72.7%; n=221) were aware of the disease, 54.3% (n=165) had poor knowledge of mpox. While 60.5% (n=184) considered mpox a serious disease, 60.2% (n=182) were willing to receive the mpox vaccine, though concerns about side effects and mistrust in health systems were major barriers. Sex (χ Conclusions: The study revealed limited knowledge of mpox, low perceived risk and poor vaccine acceptance, despite relatively high awareness in the study population. Targeted public health education and confidence-building strategies are valuable to boost vaccine uptake in these at-risk groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.